Company Overview of Precision BioSciences, Inc.
Precision BioSciences, Inc., a biotechnology company, engages in developing and commercializing therapeutics and services based on genomic molecular biology. It offers Biotherapeutics, a directed nuclease editor (DNE) therapeutic targeted to enable the in situ correction of genes responsible for human diseases; Biotools, an engineered DNE meganucleases used to engineer cell lines for disease models or optimize cell lines for the biomanufacturing of protein vaccines and therapeutics; and PlantSciences, a custom DNE meganucleases that enable site-specific engineering of row crops and biofuel feedstock. The company was founded in 2006 and is based in Research Triangle Park, North Carolina.
302 East Pettigrew Street
Dibrell Building Suite A-100
Durham, NC 27701
Founded in 2006
Key Executives for Precision BioSciences, Inc.
Co-Founder, Chief Executive Officer and Director
Chief Operations Officer and Chief Financial Officer
Senior Vice President of Gene Therapy
Senior Vice President of Cell Therapy
Compensation as of Fiscal Year 2015.
Precision BioSciences, Inc. Key Developments
Precision BioSciences Announces Management Changes
Sep 2 15
Precision BioSciences, announced the appointment of Gene Liau, Ph.D., as Senior Vice President, Gene Therapy and Bruce McCreedy, Ph.D., as Senior Vice President, Cell Therapy. Dr. Liau joins the company from Pfizer where, as Executive Director, he led External R&D for the Rare Disease Unit and spearheaded the Pfizer Gene Therapy initiative. Prior to Pfizer, Dr. Liau led groups at Novartis and Shire working on cardiovascular/metabolic diseases, gene therapy, and rare diseases. Before entering industry, Dr. Liau was a Tenured Professor at the George Washington University Medical Center and Jerome H. Holland Laboratory at the American Red Cross. Dr. McCreedy joins the company from NexImmune, where he served as Chief Development Officer and Executive Vice President of Research and Development. Before joining NexImmune, Dr. McCreedy served in leadership functions at Roche, LabCorp, Triangle Pharmaceuticals, Metabolon, and Fulcrum Pharma.
Precision BioSciences, Inc. Announces Board Appointments
May 11 15
Precision BioSciences, Inc. announced the closing of a $25.6 million Series A financing led by venBio. Joining in the oversubscribed financing are Fidelity Biosciences, Amgen Ventures, Baxter Ventures, Osage University Partners, the Longevity Fund, and two well-known public market investors. Robert Adelman of venBio and Ben Auspitz of Fidelity Biosciences will join Precision's Board alongside Precision's Chief Executive Officer, Matthew Kane and Chief Scientific Officer, Derek Jantz.
Danziger Innovations Ltd. and Precision BioSciences, Inc. Announce Successful Genome Modification Collaboration in Ornamental Plants
Mar 20 14
Danziger Innovations Ltd. and Precision BioSciences, Inc. announced that they have successfully generated site-specific genome modifications in petunia and jasmine tobacco by combining Precision's Directed Nuclease Editor (DNE) gene editing technology with Danziger's MemoGene gene delivery system. This successful research effort was aimed at genetic control of flower color but researchers at Precision and Danziger believe that the approach can be used more broadly to address genome engineering challenges in plants that are recalcitrant to existing transformation methods without requiring the insertion of foreign DNA into the plant genome.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 30, 2015